Leukotriene D4 receptor antagonist montelukast  alleviates protamine sulphate-induced changes  in rat urinary bladder.
What's known on the subject? and What does the study add? The mastocytosis in detrusor muscle and the leaky epithelium in interstitial cystitis were the most studied features. In this study the leaky epithelium was shown using the ruthenium red staining in electron microscopy and uroplakin distribution in light microscopy besides the mast cell concentration in detrusor muscle using tryptase immunohistochemistry.


OBJECTIVE
• To study the effects of montelukast (ML), a leukotriene receptor antagonist which has been shown to be effective in inhibiting the action of cysteinyl-containing leukotrienes, on protamine sulphate (PS)-induced changes in rat urinary bladder.


METHODS
• Wistar female rats were catheterized and intravesically infused with PBS (control group) or PS (PS group) dissolved in PBS twice in 24 h. • In the PS-applied and ML-treated group (PS + ML group) after the 10 mg/kg PS instillation, ML was injected i.p. twice daily for 3 days. • The urinary bladder was investigated for general morphology under a light microscope. • Tryptase immunohistochemistry was used to observe mast cell distribution and activation. Uroplakin distribution was also identified with immunohistochemistry.


RESULTS
• Alterations of glycosaminoglycan (GAG) and urothelial permeability were seen with ruthenium red (RR) staining techniques under a transmission electron microscope, and topographical changes of luminal urothelial structure were seen with a scanning electron microscope. • Biochemically malondialdehyde (MDA) and gluthatione (GSH) concentrations were analysed. In the PS group, there was degenerated urothelium with irregular uroplakin distribution, increased inflammatory cell infiltration, increased number of both granulated and activated mast cells, irregularity of GAG and penetration of RR into the intercellular spaces and dilated tight junctions. • In PS + ML group, there was relatively regular uroplakin distribution, a decrease in inflammatory cell infiltration, a decreased number of both activated and granulated mast cells in the mucosa, regular GAG and no penetration of RR into the intercellular areas, and regular tight junctions in most regions. • The significant decrease in MDA and the increased GSH concentrations in the PS + ML group was in accordance with the histological findings.


CONCLUSIONS
• Montelukast appears to have a protective function in the bladder injury model via the anti-inflammatory effects of this leukotriene receptor antagonist.
Çetinel
Sule
S
Department of Histology and Embryology, School of Medicine, Marmara University, Istanbul, Turkey.
Çanıllıoğlu
Yasemin Ersoy
YE
Çikler
Esra
E
Sener
Göksel
G
Ercan
Feriha
F
D000085:Acetates / Q000627:therapeutic use*; D000818:Animals; D002452:Cell Count; D003521:Cyclopropanes; D018856:Cystitis, Interstitial / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004195:Disease Models, Animal; D005260:Female; D005978:Glutathione / Q000378:metabolism; D006025:Glycosaminoglycans / Q000378:metabolism; D007150:Immunohistochemistry; D020024:Leukotriene Antagonists / Q000627:therapeutic use*; D008315:Malondialdehyde / Q000378:metabolism; D008407:Mast Cells / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D046529:Microscopy, Electron, Transmission; D011479:Protamines / Q000633:toxicity; D011804:Quinolines / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013440:Sulfides; D053802:Tryptases / Q000378:metabolism; D001743:Urinary Bladder / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure*; D019459:Urothelium / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure
D000085:Acetates; D003521:Cyclopropanes; D006025:Glycosaminoglycans; D020024:Leukotriene Antagonists; D011479:Protamines; D011804:Quinolines; D013440:Sulfides; D008315:Malondialdehyde; D053802:Tryptases; D005978:Glutathione; C093875:montelukast